Search results
Results from the WOW.Com Content Network
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York.The company was founded in 1988. [2] Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company branched out into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a ...
List of cities in South America; Territorial claims in Antarctica; List of cities surrounded by another city; List of cities by GDP; List of cities by elevation; List of cities by time of continuous habitation; List of cities proper by population; List of cities with the most skyscrapers; List of cities with more than one commercial airport
List of capitals and larger cities by country; List of current and former capital cities within U.S. states; List of metropolitan areas by population; List of the world's most populous cities; List of cities in India; List of planned cities; List of city nicknames in the United States; List of towns; List of places in London; List of Brooklyn ...
Pharma giant Regeneron is spending $119.5M on the world’s largest, most diverse genetic database using DNA from patient volunteers ... Regeneron invested $119.5 million in Truveta’s Series C ...
For premium support please call: 800-290-4726 more ways to reach us
Regeneron will also get a tax break on about $50 million of the renovation costs at the site, with exemptions of up to about $4.19 million in state and local sales taxes, according to IDA documents.
List of largest cities by area Notes ^ For urban/metropolitan areas that have more than one core city , the figure for their city proper should use either the most populous one (e.g. Dallas for Dallas–Fort Worth metroplex ) or the best-known one (e.g. Manila for Metro Manila , instead of Quezon City ).
Shares of Regeneron were down over 2% in premarket trading. Eylea, jointly developed with Bayer AG, has driven Regeneron's earnings for years, but sales have now come under pressure, partly from ...